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AbstrACt
Objectives To evaluate adherence and acceptability of 
intermittent vaginal probiotic or antibiotic use to prevent 
bacterial vaginosis (BV) recurrence.
Design Repeated adherence and acceptability 
assessments using mixed methods within a pilot 
randomised controlled trial.
setting Research clinic in Kigali, Rwanda.
Participants Rwandan women with high sexual risk.
Interventions Women diagnosed with BV and/
or trichomoniasis were randomised to four groups 
(n=17 each) after completing metronidazole treatment: 
behavioural counselling only, or behavioural counselling 
plus 2- month intermittent use of oral metronidazole, 
Ecologic Femi+ (EF+) vaginal capsule or Gynophilus LP 
(GynLP) vaginal tablet.
Outcome measures Adherence and acceptability 
were assessed by structured face- to- face interviews, 
semi- structured focus group discussions and in- depth 
interviews, daily diaries and counting of used/unused 
study products in randomised women (n=68). Vaginal 
infection knowledge was assessed by structured face- 
to- face interviews in randomised women and women 
attending recruitment sessions (n=131).
results Most women (93%) were sex workers, 99.2% 
were unfamiliar with BV and none had ever used 
probiotics. All probiotic users (n=32) reported that insertion 
became easier over time. Triangulated adherence data 
showed that 17/17 EF+ users and 13/16 GynLP users used 
≥80% of required doses (Fisher’s exact p=0.103). Younger 
age (p=0.076), asking many questions at enrolment 
(p=0.116), having menses (p=0.104) and reporting 
urogenital symptoms (p=0.103) were non- significantly 
associated with lower perfect adherence. Women believed 
that the probiotics reduced BV recurrence, but reported 
that partners were sometimes unsupportive of study 
participation. Self- reported vaginal washing practices 
decreased during follow- up, but sexual risk behaviours did 
not. Most women (12/15) with an uncircumcised steady 
partner discussed penile hygiene with him, but many 
women found this difficult, especially with male clients.
Conclusions High- risk women require education about 
vaginal infections. Vaginal probiotic acceptability and 
adherence were high in this cohort. Our results can be 
used to inform future product development and to fine- 
tune counselling messages in prevention programmes.
trial registration number NCT02459665.
IntrODuCtIOn
Bacterial vaginosis (BV) is a vaginal condition 
in which fastidious anaerobes such as Gard-
nerella vaginalis increase while beneficial, lactic 
acid–producing lactobacilli decrease.1 Often 
asymptomatic, it is associated with increased 
risks of sexually transmitted infections (STIs) 
and HIV acquisition, pelvic inflammatory 
disease and adverse pregnancy outcomes.2–5 
Although BV is treatable with antibiotics, 
the risk of recurrence is high.6 7 The preva-
lence of BV varies among regions and ethnic 
groups but is highest in sub- Saharan Africa, 
where it is estimated at 30%–50%.8
Vaginally administered probiotics 
containing lactobacilli are considered 
a promising new strategy to restore a 
strengths and limitations of this study
 ► We conducted this research in the context of a pilot 
randomised controlled trial, and statistical power 
was therefore limited.
 ► We triangulated different sources of adherence data 
to maximise accuracy and used a mixed- methods 
approach to evaluate acceptability.
 ► We could not directly compare experiences with, 
and opinions about, the two different vaginal pro-
biotics because each woman used only one product 
and qualitative data depth was suboptimal.
 ► Social desirability bias may have affected some of 
the results.
 ► The results of this study may not be generalisable 
to women at lower risk of sexually transmitted or 
urogenital infections.
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lactobacilli- dominated vaginal microbiota during and/
or after antibiotic treatment, or to prevent BV.9 While 
some probiotics have been available on the market for 
several years, clinical trials to support beneficial effects 
have only recently been initiated for most products.10–13 
Future uptake and adherence of a vaginal probiotic, once 
proven efficacious, is determined to a large extent by its 
acceptability in target populations. The acceptability, in 
turn, depends on factors such as characteristics of the 
target population, characteristics of and experiences with 
the product, types of sexual relationships and partner 
support, and community perceptions.14 15
We conducted a clinical trial of intermittent use of two 
vaginal probiotics and oral metronidazole to prevent BV 
recurrence in Rwandan women who had been treated for 
BV and/or Trichomonas vaginalis (TV). We used qualita-
tive and quantitative research methods to assess adher-
ence and acceptability with vaginal probiotic use. We 
triangulated various sources of adherence data to obtain 
adherence estimates per woman for each period of inter-
mittent product use in between study visits, and deter-
mined correlates of adherence.
MethODs
The pilot clinical trial took place from June 2015 to 
February 2016 at the Rinda Ubuzima research clinic in 
Kigali, Rwanda. The trial was a pilot trial with a modest 
sample size at the request of the funder. Women who 
had been successfully treated for BV/TV with a 7- day 
course of oral metronidazole (Tricozole; Laboratory & 
Allied, Nairobi, Kenya) were randomised to four inter-
vention groups (n=17 each) to prevent BV recurrence: 
behavioural counselling only (controls), or behavioural 
counselling plus intermittent use of two different vaginal 
probiotics or oral metronidazole for 2 months. The 
behavioural counselling included counselling on safer 
sex, vaginal hygiene (including discouragement of intra-
vaginal washing) and penile hygiene (ie, encouragement 
of cleansing the penis, including underneath the fore-
skin) because these behaviours are known to reduce BV 
recurrence risk somewhat.6 16 We counselled all women 
in all randomisation groups because we considered it 
unethical to withhold this information from women at 
risk. Women were seen at screening, enrolment (product 
use initiation, if applicable), day 7, month 1, month 
2 (product use cessation, if applicable) and month 6. 
Product efficacies were not known during the trial, and 
the efficacy results of the pilot trial are reported else-
where.17 Briefly, the vaginal probiotics did improve the 
vaginal environment (increased lactobacilli and reduced 
BV- associated bacteria) compared with counselling only, 
but not as much as oral metronidazole did.
study population
Women aged 18–45 at risk of HIV/STIs (defined as having 
had more than one sex partner and/or having been 
treated for an STI and/or BV in the last 12 months) were 
eligible for enrolment if they were confirmed HIV nega-
tive, non- pregnant, diagnosed with BV and/or TV, and 
cured after 7- day oral metronidazole treatment. Other 
clinical exclusion criteria were applied but were rare.17 
Women were recruited by study staff with the assistance 
of Community Mobilisers who had strong ties with local 
high- risk women (particularly sex workers).
study products and dosing
Ecologic Femi+ (EF+; Winclove Probiotics, Amsterdam, 
Netherlands) is a vaginal capsule containing lyophilised 
lactic acid–producing bacteria. EF+ was used once per 
day for 5 days followed by thrice weekly, for 2 months. 
Gynophilus LP (GynLP; Biose, Aurillac, France) is a 
tablet containing the Lactobacillus rhamnosus Lcr35 strain. 
The tablet disintegrates in the vagina and forms a gel that 
slowly releases the probiotic bacteria. GynLP was used 
once every 4 days for 2 months. The first dose was inserted 
at the clinic under direct observation of a clinician, and 
remaining doses were self- administered at home. Women 
were asked not to cleanse or insert other products into 
the vagina after probiotic insertion to allow the probiotics 
to dissolve. They were also told that they were allowed to 
cease probiotic use during menses, but were encouraged 
to continue. Intermittent metronidazole use was chosen as 
a positive control intervention because studies conducted 
in the USA and Kenya have shown a 30%–40% reduction 
in BV recurrence.18 19 Metronidazole users took 500 mg 
generic oral metronidazole (Laboratory & Allied) twice 
weekly for 2 months. The rationale for selecting these 
study products and their dosing schedules can be found 
in the manuscript describing the efficacy results of the 
pilot trial.17 Participants and clinicians were not blinded.
Acceptability, adherence, behavioural and vaginal infection 
knowledge assessments
Acceptability was assessed at the enrolment visit prior to 
product use initiation and at the month 2 visit after the 
full 2 months of use. Adherence was assessed during the 
intervention period, at the day 7, month 1 and month 
2 visits. Sexual and other behaviours were assessed at all 
study visits. Participants were interviewed face- to- face in 
Kinyarwanda by a trained study nurse using structured 
questionnaires with multiple- choice questions, questions 
requiring a number or date, and an adherence self- rating 
scale (from 0 to 10). In between visits, participants used 
pictorial diary cards (online supplementary material 
figure 1) to record daily episodes of product use, vaginal 
sex, condom use and vaginal practices. Those using study 
products returned the product packaging and unused 
products (if applicable) to their clinic visits, where they 
were counted by study staff. Any discrepancies between 
data sources were discussed with participants and the 
consensus assessments were recorded on the question-
naires. The adherence data based on the self- rating scale, 
the diary card and the returned product packaging were 
triangulated by the data analyst at the data analysis stage. 
In addition, 131 women were interviewed about their 
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Figure 1 Flowchart of the study. *Totals to 110 reasons 
among 102 women because there could be more than one 
reason per woman. †Reasons: outside of metronidazole 
treatment window (n=5), enrolment target already met (n=4), 
has a mental disorder (n=1), did not complete screening 
procedures and was subsequently lost to follow=up (n=1), 
withdrew consent during the screening visit because she 
thought the reimbursement was too low (n=1). ‡Reasons: 
moved away from Kigali (n=2), lost interest because 
symptoms resolved (n=1), and was verbally harassed 
by partner and sister about study participation (n=1). 
Acceptability assessments were made at enrolment and 
at the M2 visit. Adherence assessments were made using 
self- rated assessments, pictorial diary cards, and returned 
packaging at the D7, M1 and M2 visits (after which product 
use was ceased). The vaginal infection knowledge survey 
was held at recruitment sessions in the community and 
at the enrolment visit. Changes in sexual risk- taking and 
vaginal practices were assessed at each follow- up visit and 
compared with answers given during the enrolment visit. 
All of these themes were discussed during the eight FGDs 
and IDIs. BV, bacterial vaginosis; D7, day 7 visit; FGD, focus 
group discussion; IDI, in- depth interview; M1/2/6, month 
1/2/6 visit; RU, Rinda Ubuzima; TV, Trichomonas vaginalis.
knowledge of vaginal infections (such as BV and STIs) 
using a structured questionnaire during recruitment 
sessions (n=61; regardless of eligibility) and at enrolment 
visits (n=70; this included the 68 randomised women, and 
two women who attended enrolment visits but turned 
out to be ineligible; figure 1). Women were interviewed 
before being counselled at study visits or before receiving 
information at recruitment sessions. This questionnaire 
contained multiple- choice and open- ended questions. 
Responses to the open- ended questions were categorised 
and discussed by two different researchers until consensus 
about the answer categories was reached.
Four semi- structured focus group discussions (FGDs) 
with 7–11 participants per group (total n=38), and semi- 
structured individual in- depth interviews (IDIs) with four 
additional participants, were held. The main themes of 
these FGDs and IDIs were experiences with and opinions 
of the study products, sexual behaviour and vaginal prac-
tices. Women randomised to the behavioural counselling 
only group were not approached for the FGDs and IDIs, 
but all other randomised participants who had completed 
their product use period were approached until data satu-
ration had been achieved. The interviews were unlinked 
anonymous, and women used pseudonyms to enable 
them to talk freely despite the fact that the discussions 
and interviews were taped. All interviews took place 
between November 2015 and March 2016, were held in 
Kinyarwanda, recorded on tape, transcribed verbatim 
and translated into English. The FGD and IDI transcripts 
were read and discussed by three researchers (MCV, MU 
and JHHMvdW) at regular intervals. The Chief Investi-
gator (JHHMvdW) decided that data saturation had been 
met when the fourth FGD and the fourth IDI transcript 
had become available in March 2016.
Data analysis
The primary outcomes of this study were acceptability 
and triangulated adherence in women randomised to 
study product use. Secondary outcomes included vaginal 
infection knowledge of the target population more 
broadly, and behavioural changes (of the behaviours 
included in the counselling messages) in all randomised 
women. Questionnaire data were analysed using Stata 
V.13 (StataCorp, College Station, TX, USA). The propor-
tion of women with ≥80%/≥90%/100% adherence in 
the probiotic groups were compared by Fisher’s exact 
tests. Changes in self- reported vaginal practices and 
sexual behaviours over time were tested using McNe-
mar’s test for binary outcomes, and Wilcoxon’s signed- 
rank test for continuous outcomes. To study associations 
of participant characteristics with triangulated adher-
ence, we used bivariable mixed- effects models, with 
perfect adherence (defined as having used all doses as 
instructed) per interval between study visits during the 
intervention period as the outcome, participant identifi-
cation numbers as the random effect and one participant 
characteristic at the time as the fixed effect. We could not 
determine correlates of acceptability due to limited vari-
ation in the acceptability data (reported acceptability was 
high throughout the trial).
The FGD and IDI transcripts were coded using NVivo 
V.10.0 (QSR International, Melbourne, Australia) by one 
single researcher (MCV). The discussions and interviews 
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were semi- structured, with the aforementioned themes 
and associated codes prepared a priori, as well as new 
elements that emerged from the data. The codes were 
derived from an acceptability framework that has been 
used in studies of vaginal products for contraception or 
HIV prevention.14 15 20 Components of the framework 
include study population characteristics, product attri-
butes, sexual encounter and relational attributes, and the 
contextual environment (eg, community perceptions of 
product use).
ethical statement
All participants provided written consent for study partic-
ipation and separate consent for participation in FGDs/
IDIs. All non- married participants aged 18–20 also 
required parental/guardian consent per Rwandan law at 
the time of the study. The participants received 3 GBP 
per visit (in local currency) as a reimbursement for time 
and transport costs. Care was taken to protect participant 
privacy and confidentiality. The study was sponsored by 
the University of Liverpool.
Participant and public involvement
As part of the FGDs/IDIs, a subset of the enrolled partic-
ipants were invited to comment on study design and 
experiences with the interventions. Participants were not 
invited to develop outcomes, interpret the results, or to 
contribute to the writing or editing of this document for 
readability or accuracy. The preliminary results of this 
study were discussed with 32 stakeholders during a work-
shop held at the Ministry of Health in Kigali, Rwanda, in 
December 2017. These stakeholders included representa-
tives of the Ministry of Health, the National University of 
Rwanda, the National Ethics Committee, local hospitals 
and clinics, and local non- governmental and women’s 
organisations.
results
baseline characteristics
We screened 176 women: bacterial STI prevalence was 
31.3% and BV prevalence by Gram stain Nugent scoring 
was 47.9%. All 68 randomised women were treated for BV 
and/or TV prior to randomisation and at risk of HIV/
STIs, with 93.1% reporting having exchanged sex for 
money and/or goods in the previous month (figure 1, 
online supplementary material table 1). We collected 
29.93 person- years of data. Four women withdrew their 
informed consent during the study (for reasons unre-
lated to study product acceptability). None were lost to 
follow- up.
Adherence
Triangulated adherence was high: 17/17 (100%) of EF+ 
users and 13/16 (81.3%) of GynLP users used ≥80% of 
required doses (Fisher’s exact p=0.103; table 1), and these 
percentages were 15/17 (88.2%) and 11/16 (68.8%) for 
≥90% (p=0.225), and 10/17 (58.8%) and 8/16 (50%) 
for 100% of required doses (p=0.732), respectively. In 
comparison, these percentages were 15/17 (88.2%), 
14/17 (82.4%) and 12/17 (70.6%), respectively, for oral 
metronidazole users. Reported reasons of non- adherence 
to vaginal probiotics during face- to- face interviews were 
‘simply forgetting’ (n=9), experiencing side effects 
(n=2), menses (n=2), and being away from home and 
having left products at home (n=1). Additional reasons 
for missing doses mentioned during FGDs/IDIs were 
being drunk (n=2) and being confused about the dosing 
schedule (n=2). Only one woman in the metronidazole 
arm reported missing doses due to experiencing side 
effects. Most women in FGDs reported using all doses 
as instructed and finding it easy to adhere, and thought 
that the diary cards served as a useful reminder to use the 
products.
Acceptability
Ease of use
No participants reported having heard about probiotics 
before study participation. After product use, all vaginal 
probiotic users reported feeling very comfortable with 
insertion and that insertion became easier over time. 
All but one woman reported inserting while lying down 
(online supplementary material table 2).
Bodily changes and product perception
During FGDs, several women using either vaginal probi-
otic reported the product (partially) “coming out” during 
the first few uses, but that this decreased after having 
gained experience. Many EF+ and GynLP users reported 
an increase in vaginal wetness, which was considered a posi-
tive attribute by most. Some women reported increased 
libido. For example, one EF+ user said: “I felt a great 
desire to [have] sex again and again”. In contrast, one 
metronidazole user reported a decrease in libido. Most 
women believed that the vaginal probiotics decreased the 
recurrence of symptomatic BV (our preliminary efficacy 
data suggest that BV incidence had in fact decreased),17 
and a few believed that they also prevented STI acquisi-
tion (the trial had insufficient statistical power to assess 
this).
Support
One social harm related to vaginal probiotic use was 
reported: a GynLP user was verbally harassed by her 
partner and her sister because of her study participation, 
and opted to withdraw her informed consent. Reports 
of partner, family and community support during the 
FGDs/IDIs were mixed: some women reported problems 
with loved ones. Negative reactions from male partners 
were more often based on suspicions about study partici-
pation than the products themselves. One EF+ user said: 
“He [her partner] did not accept that. He asked me to 
go together with him to the clinic [a local health centre] 
and check if I am not HIV- positive”. Another participant 
using metronidazole mentioned wanting to join the study 
to her husband, who forbade her to participate. However, 
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Table 1 Adherence to study interventions
Adherence to study products Metronidazole (n=17) EF+ (n=17) GynLP (n=16)
Adherence Enr–D7, median % (IQR) 100 (100–100) 100 (100–100) 100 (100–100)
Adherence D7–M1, median % (IQR) 100 (100–100) 100 (100–100) 100 (91.7–100)
Adherence M1–M2, median % (IQR) 100 (100–100) 100 (100–100) 100 (92.3–100)
Overall adherence Enr–M2, median % (IQR) 100 (96.3–100) 100 (100–100) 98.3 (89.3–100)
Overall adherence Enr–M2 n (%)
  Perfect* 12 (70.6) 10 (58.8) 8 (50.0)
  Adherence ≥90% 14 (82.4) 15 (88.2) 11 (68.8)
  Adherence ≥80% 15 (88.2) 17 (100) 13 (81.3)
No of times menses Enr–M2 n (%)†
  Never 7 (41.2) 4 (23.5) 2 (12.5)
  Once 6 (35.3) 5 (29.4) 4 (25.0)
  Twice 4 (23.5) 8 (47.1) 10 (62.5)
Did not use product during menses at least once n (%)
Yes 4 (23.5) 3 (17.6) 5 (31.3)
NA (never had menses) 7 (41.2) 4 (23.5) 2 (12.5)
Self- reported reasons for non- adherence‡ Metronidazole EF+ GynLP
D7: Self- reported reasons why not able to use all doses as instructed 
n (%)§
  Simply forgot 0 2 (11.8) 0
  Product had side effects 0 0 1 (6.7)¶
M1: Self- reported reasons why not able to use all doses as instructed 
n (%)§
  Simply forgot 1 (6.3) 1 (5.9) 1 (6.3)
  Product had side effects 1 (6.3)** 0 1 (6.3)§§
  Did not like product for another reason 1 (6.3)** 0 0
  Other 1 (6.3)†† 1 (5.9)‡‡ 2 (12.5)¶¶
M2: Self- reported reasons why not able to use all doses as instructed 
n (%)§
  Simply forgot 1 (6.3) 2 (11.8) 3 (18.8)
  Travelled and forgot to take product 1 (6.3) 0 1 (6.25)
  Other 0 1 (5.9)*** 1 (6.3)†††
D7: Participant thinks she used product correctly most of the time n 
(%)
17 (100) 16 (94.1) 14 (93.3)
M1: Participant thinks she used product correctly most of the time n 
(%)
13 (86.7) 17 (100) 11 (68.8)
M2: Participant thinks she used product correctly most of the time n 
(%)
15 (93.7) 16 (94.1) 14 (87.5)
*Defined as 100% of the prescribed doses used at the prescribed times after nurse review of the participant’s diary card and returned used 
packaging and unused product.
†Number of times menses in the control group: never 2 (11.8%), once 3 (17.8%), twice 11 (64.7%) and thrice 1 (5.9%).
‡Numbers of participants per randomisation group may very slightly due to loss to follow- up. Participants with ≥90% adherence not shown.
§Multiple answers possible.
¶Participant reported vulval itching and burning when passing urine.
**Participant reported mild gastritis and wanting to withdraw from the study anyway.
††Participant reported receiving oral metronidazole therapy for 7 days due to infection.
‡‡Participant reported having menses twice in 1 month; decided to use less of her product until the next study visit.
§§Participant reported genital itching, genital burning and pain during sex.
¶¶One participant reported missing the D7 study visit and therefore running out of supplies. Another participant reported not to have used the 
study product during menses (which she was allowed to do).
***Participant reported being drunk and therefore forgetting to take the study product.
†††Participant reported taking the study product correctly but that the product came out during menses.
D7, day 7 visit; EF+, Ecologic Femi+; Enr, enrolment visit; GynLP, Gynophilus LP; IQR, inter- quartile range; M1/2, month 1/2 visit; NA, not 
applicable.
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Table 2 Changes in reported vaginal cleansing practices and (sexual) behaviour between the enrolment and the M6 visit
Self- reported sociodemographic characteristics
Enr
(n=71)
M6
(n=65)
OR (95% CI)*
P value*
Reports using no products inside the vagina (other 
than for managing menses; all participants) n (%)
35 (49.3) 53 (81.5) 5.2 (1.96 to 17.34)
<0.001
Reports using no products inside the vagina 
(other than for managing menses; controls and 
metronidazole users only)† n (%)
15 (44.1) 27 (79.4) 13.0 (1.95 to 552.5)
0.002
Reports using water only n (%) 23 (32.4) 10 (15.4) 0.37 (0.13 to 0.92)
0.029
Reports using water and soap n (%) 3 (4.2) 2 (3.1) 0.67 (0.06 to 5.82)
1.00
Reports using paper, cloth or cotton wool n (%) 9 (12.7) 0 (0) 0.13 (0.00 to 0.93)‡
0.008
Reports using traditional herbs, stones, powders as 
vaginal cleansing practice n (%)
1 (1.4) 1 (1.5) 1.00 (0.01 to 78.5)‡
1.00
Mean weekly frequency of vaginal practices (95% CI) 2.15
(0.97 to 3.34)
0.64
(0.18 to 1.11)
NA
0.328
Median no of sex partners in last month at baseline 
or per month during follow- up period (IQR)
5
(3–16)
2
(1–4)
NA
<0.001
Any condom use reported in past 2 weeks (Enr) 
or since last study visit (M6), vs no condom use 
reported n (%)
64 (90.1) 60 (92.3) 1.67 (0.32 to 10.7)
0.727
Reports exchanging sex for money/goods in past 
month (Enr) or since last study visit (M6) n (%)
65 (91.5) 58 (89.2) 0.80 (0.16 to 3.72)
1.00
*McNemar’s OR and p value for binary variables and Wilcoxon signed- rank test p value for continuous variables, comparing the response at 
M6 with the response at Enr. ORs with 95% CI were also calculated for binary pre–post data.
†n=34.
‡To enable calculation of effect measures, a zero value was replaced by 1.
CI, confidence interval; Enr, enrolment visit; IQR, inter- quartile range; M6, month 6 visit; NA, not applicable; OR, odds ratio.
she decided to join anyway: “he did not know that I was 
using the study product, because he had refused me to 
join [the] study before… I used them [the study prod-
ucts] without informing him”. All sex workers except one 
stated that they had not discussed study participation with 
male clients.
Worries and concerns
In the FGDs, one woman reported hearing rumours 
prior to enrolling that vaginal products “can damage the 
uterus or cause tumours in the womb”. However, most 
participants thought that vaginal probiotics would be 
acceptable to Rwandan women. One GynLP user argued: 
“They [already] give us vaginal pills”, by which she meant 
vaginal medications for yeast infections. We did not ask 
women explicitly whether they would be willing to pay for 
the products, but some women mentioned spontaneously 
in FGDs that they were concerned about future product 
availability and pricing. They hoped that probiotics would 
be distributed cheaply through the Rwandan Mutuelle 
public health insurance because they would otherwise 
be inaccessible to many women. One metronidazole user 
was concerned about a limited applicability of probi-
otics because BV is not diagnosed by laboratory testing 
in Rwanda: “They do not have adequate medical instru-
ments to test diseases, you tell the physician how […] you 
feel and by guessing the disease, he gives you at least four 
medications, saying that you may have trichomonas, you 
may have syphilis, you may have gonorrhoea [she refers to 
syndromic management21 22]. At health centre- level they 
do not have medical equipment to test diseases, meaning 
that they will not know who to give that [probiotic/antibi-
otic maintenance therapy] medication”.
Vaginal practices and sexual risk-taking
At enrolment, 35/71 (49.3%) of the women reported to 
never use products inside the vagina, and at month 6, 
this increased to 53/65 (81.5%) (OR 5.2, 95% CI 1.96 to 
17.34; table 2). During FGDs, some women understood 
that vaginal washing practices may increase the risk of 
vaginal infection, but others did not. A participant stated: 
“You get them [i.e., vaginal diseases] anyway… whether 
you wash or not”. In one FGD, 10 of 11 participants 
(90.9%) stated having ceased vaginal practices thanks to 
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Table 3 Participant characteristics associated with perfect adherence
Participant characteristics
EF+ and GynLP users
EF+, GynLP and oral 
metronidazole users
OR (95% CI) P value OR (95% CI) P value
Randomisation group: GynLP vs EF+ 0.68 (0.22 to 2.11) 0.505 ND ND
Randomisation group
  EF+ vs metronidazole ND ND 0.53 (0.15 to 1.81) 0.308
  GynLP vs metronidazole 0.36 (0.11 to 1.23) 0.103
Age in years: ≥30 years vs <30 2.66 (0.90 to 7.82) 0.076 1.60 (0.61 to 4.15) 0.336
Marital status
  Married vs never married 0.97 (0.14 to 6.58) 0.976 1.17 (0.20 to 6.99) 0.865
  Divorced vs never married 1.18 (0.29 to 4.79) 0.912 1.39 (0.42 to 4.57) 0.586
  Widowed vs never married ND 0.991 ND 0.99
At least some schooling vs no schooling 1.20 (0.59 to 2.45) 0.619 0.80 (0.22 to 2.95) 0.74
No of sex partners last month: five or more vs four or 
less.
0.58 (0.18 to 1.83) 0.351 0.49 (0.17 to 1.37) 0.173
Exchanged sex for money/goods past month ND 0.99 ND 0.986
Nurse reported participant asked questions at Enr
  Yes, many vs none 0.19 (0.02 to 1.52) 0.116 0.15 (0.02 to 1.19) 0.072
  Yes, a few vs none 0.83 (0.24 to 2.83) 0.761 0.83 (0.27 to 2.57) 0.744
Had menses during study visit interval 0.41 (0.14 to 1.20) 0.104 0.26 (0.09 to 0.70) 0.008
Reported alcohol consumption during study
  Once or twice per week vs never 0.54 (0.14 to 2.12) 0.373 0.34 (0.11 to 1.08) 0.068
  More than twice per week vs never 0.92 (0.18 to 4.81) 0.92 0.81 (0.19 to 3.49) 0.774
Reported at least one urogenital symptom during 
study interval vs none
0.11 (0.01 to 1.56) 0.103 0.30 (0.04 to 2.16) 0.231
Reported at least one adverse event during study visit 
interval (excluding urogenital symptoms) vs none
0.43 (0.10 to 1.83) 0.253 0.55 (0.15 to 2.05) 0.371
Sociodemographic characteristics associated with perfect adherence in bivariable mixed effects models, in the enrolment–D7, D7–M1 and 
M1–M2 study visit intervals.
CI, confidence interval; D7, day 7 visit; EF+, Ecologic Femi+; Enr, enrolment visit; GynLP, Gynophilus LP; M1, month 1 visit; M2, month 2 visit; 
ND, non- determinable; OR, odds ratio.
the study counselling. It should be noted that in contrast 
to many other African populations, Rwandan women use 
vaginal practices to increase rather than reduce vaginal 
lubrication. Women mentioned the use of herbs (umush-
ishiro), Vaseline and oils for this purpose. Self- reported 
sexual risk taking by face- to- face interview did not change 
over time, except for a significant reduction in reported 
numbers of sex partners in the previous month at month 
6 compared with enrolment. No women in FGDs/
IDIs mentioned adopting safer sex practices (such as 
consistent condom use) in response to the counselling 
messages. During face- to- face interviews at the month 2 
visit, 12 of 15 women (80%) who had an uncircumcised 
main sex partner reported asking him to regularly clean 
his penis in the future (online supplementary material 
table 2). While most women in FGDs understood that 
using condoms and improved penile hygiene could 
reduce BV rates (as shown in6 16), some mentioned that 
they found it difficult to discuss these topics with male 
partners. One participant stated that this is especially 
difficult being a sex worker: “a man gives you his own 
money and you start educating him to wash!” However, 
another sex worker reported refusing sex with uncircum-
cised clients: “you leave him, because he has a lot [of] 
germs”. Several women reported discussing circumcision 
with their partners; one participant reported telling her 
husband: “It is better that you do circumcision because it is 
a good thing… you would get a chance of not contracting 
diseases”.
Correlates of adherence
In bivariable mixed- effects models including the probi-
otic groups only, no participant characteristics were 
significantly associated with perfect adherence (table 3). 
However, non- significant trends were observed. Younger 
age (p=0.076), asking many questions at enrolment 
(compared with a few questions or no questions; struc-
turally judged by a study nurse; p=0.116), having menses 
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during the previous study interval (p=0.104) and 
reporting urogenital symptoms (p=0.103) were associ-
ated with a lower likelihood of perfect adherence. When 
including oral metronidazole users, menses was signifi-
cantly associated with a lower likelihood of perfect adher-
ence (p=0.008). There were no significant associations 
between randomisation group and perfect adherence.
Vaginal infection knowledge
Almost all participants reported having heard of ‘diseases 
of the vagina’ and STIs before, but only 6/131 (4.6%) 
knew what bacteria were (table 4). The STIs most often 
spontaneously named (in numerical order) were HIV, 
gonorrhoea and syphilis; only one participant reported 
having heard of BV. After having received an explanation 
about what BV is, only one of 131 woman reported ever 
having been diagnosed with BV. Most participants could 
name at least one cause or potential consequence of 
vaginal infections. Consequences wrongfully attributed to 
vaginal infections were cervical cancer/tumours (5/131; 
3.8%), consequences to the infant such as being born 
with BV or congenital malformations (6/131; 4.6%), and 
death (4/131; 3.1%).
DIsCussIOn
Several studies of different vaginal probiotics have been 
conducted, some of them in sub- Saharan Africa.10–13 
However, none reported in- depth acceptability and 
adherence data. Our study suggests high vaginal probi-
otic acceptability and adherence in high- risk Rwandan 
women. We found no statistically significant correlates 
of perfect adherence, partially due to limited statistical 
power, but younger age, asking many questions about 
product use at enrolment, current menses and reporting 
urogenital symptoms showed trends towards a lower 
likelihood of perfect adherence. Vaginal probiotics are 
currently unavailable on the market in most African coun-
tries, and it is important to study acceptability in different 
target populations to inform product development and 
future marketing strategies. Adherence to metronidazole 
was comparable with, or slightly higher than, adherence 
reported in previously conducted studies.19 23
We could not evaluate the impact of self- reported 
acceptability aspects on adherence because almost all 
women reported very high acceptability in face- to- face 
interviews throughout the trial. Such interviews are 
known to suffer from social desirability bias. However, 
women seemed to speak freely in the FGDs, and those 
data indicate that they did not have major issues with 
product attributes or insertion. However, some women 
reported difficulties due to lack of male partner support. 
The reported increase in vaginal wetness after probiotic 
insertion was not considered problematic, as lubrica-
tion during sex is preferred by most Rwandan men and 
women.24 This might be different in other countries 
where dry sex is preferred.25 We did find a non- significant 
lower adherence to GynLP compared with EF+, which 
might be explained by differences in formulation: GynLP 
forms a gel in the vagina whereas EF+ capsules merely 
release lyophilised bacteria. Previous research indicated 
high adherence to GynLP.26 Unfortunately, the impact of 
these formulation differences was insufficiently probed 
during the FGDs; the impact of product formulation 
on acceptability and adherence should be investigated 
in future clinical trials. Participants indicated that they 
found the diary cards helpful in reminding them to use 
their products, and we believe that self- monitoring tools 
might indeed be helpful in maximising adherence and 
therefore recommend them for use in future studies.27
Our data suggest that counselling was partially effec-
tive in changing behaviours that increase BV risk. While 
these results are encouraging, it is difficult to assess to 
what extent they were influenced by social desirability 
bias. Significantly more women reported not engaging in 
vaginal practices at the end of the study, and most women 
with uncircumcised steady male partners reported having 
discussed penile hygiene with them. However, many 
women mentioned in FGDs that they found it difficult to 
discuss condom use and penile hygiene with male part-
ners, especially clients. Women reduced their sexual risks 
only to a limited extent during follow- up, reporting a 
reduction in numbers of sex partners but no differences 
in engaging in sex work and condom use in face- to- face 
interviews. We did not ask women to what extent they 
depended on sex work for subsistence. Women who only 
partially depend on sex work may find it easier to nego-
tiate with male partners.
Two probiotics- related themes that emerged from the 
stakeholders consultations that had not been raised by 
the study participants were uncertainty about long- term 
side effects (women in the pilot trial used the products 
for only 2 months) and whether probiotic bacteria (in this 
case lactobacilli) could also be delivered orally instead of 
vaginally. We have since conducted a systematic review, 
which showed that long- term safety of vaginal probiotics 
has not yet been evaluated.28
Our survey with women at recruitment sessions and 
enrolment visits showed that high- risk Rwandan women 
had heard of several STIs, but were generally unaware 
of BV, its causes and potential consequences, and what 
they can do to prevent it. Experiences with HIV show that 
public health interventions can only succeed if health-
care professionals and the public have sufficient knowl-
edge of causes and consequences of disease.29–31 High- risk 
Rwandan women (and healthcare professionals) should 
therefore be educated about BV, and vaginal probiotics 
studies should include counselling for all participants on 
vaginal diseases and how to prevent them.
limitations
Our study had limited statistical power, and social desir-
ability bias may have affected some of our results, as is 
often the case in studies of this nature. In addition, it 
should be noted that product efficacy, availability and 
cost are important determinants of acceptability, and 
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Table 4 Vaginal infection knowledge
Recruitment 
(n=61)
Enrolment 
(n=70)
Total
(n=131)
Median age (IQR) 32 (27–35)* 31 (27–35) 31 (27–35)
Has heard of diseases of the vagina before n (%) 60 (98.4) 70 (100) 130 (99.2)
Reports knowing what bacteria are before study n (%) 5 (8.2) 1 (1.4) 6 (4.6)
Reports having heard about STIs before study n (%) 61 (100) 70 (100) 131 (100)
If yes, spontaneously named, without probing† n (%)
  HIV 58 (95.1) 65 (92.9) 123 (93.9)
  Gonorrhoea 58 (95.1) 65 (92.9) 123 (93.9)
  Syphilis 44 (72.1) 59 (84.3) 103 (78.7)
  Trichomoniasis 38 (62.3) 48 (68.6) 86 (65.7)
  Hepatitis 3 (4.9) 3 (4.3) 6 (4.6)
  Yeast infection 0 3 (4.3) 3 (2.3)
  BV 0 2 (2.9) 2 (1.5)
  Urinary tract infection 1 (1.6) 1 (1.4) 2 (1.5)
  Chlamydia 0 1 (1.4) 1 (0.8)
  Herpes 0 1 (1.4) 1 (0.8)
  HPV/cervical cancer 1 (1.6) 0 1 (0.8)
Reports having heard about BV before this study n (%) 1 (1.6) 0 1 (0.8)
Spontaneously reported reasons why women get vaginal disease, without 
probing† n (%)
  Poor toilet hygiene 37 (60.7) 40 (57.1) 77 (58.8)
  Multiple sex partners 28 (45.9) 36 (51.4) 64 (48.9)
  After sex 25 (41.0) 30 (43.0) 55 (42.0)
  Dirty underwear 19 (31.2) 35 (50.0) 54 (41.2)
  Poor vaginal hygiene 26 (42.6) 22 (31.4) 48 (36.6)
  Poor penile hygiene of male partner(s) 4 (6.6) 17 (24.3) 21 (16.0)
  Traditional vaginal practices and washing 3 (4.9) 12 (17.1) 15 (11.5)
  New sex partner 6 (9.8) 3 (4.3) 9 (6.9)
  Use of contraception 1 (1.6) 3 (4.3) 4 (3.1)
  (Improper) use of sanitary pads or tampons 1 (1.6) 3 (4.3) 4 (3.1)
  Other 3 (4.9)‡ 1 (1.4)§ 4 (3.1)
  Cannot name any reasons 1 (1.6) 0 1 (0.8)
Spontaneously reported negative consequences of vaginal disease being 
named, without probing† n (%)
  Foul smell from the vagina 30 (49.2) 39 (56.5) 69 (53.1)
  Difficulty getting pregnant 18 (29.5) 33 (47.8) 51 (39.2)
  Miscarriage 16 (26.2) 33 (47.8) 49 (37.7)
  Abnormal vaginal discharge 12 (19.7) 28 (40.6) 40 (30.8)
  Baby born too early 16 (26.2) 22 (31.9) 38 (29.2)
  Severe infection/fever of the woman 7 (11.5) 7 (10.1) 14 (10.8)
  Infection/fever of the newborn baby 5 (8.2) 3 (4.4) 8 (6.1)
  Itching 4 (6.6) 4 (5.8) 8 (6.1)
  Other consequences to the baby: being born with BV, congenital 
malformations and others
3 (4.9) 3 (4.4) 6 (4.6)
  Cervical cancer or tumours 2 (3.3) 3 (4.4) 5 (3.8)
  Death 4 (6.6) 0 4 (3.1)
Continued
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Recruitment 
(n=61)
Enrolment 
(n=70)
Total
(n=131)
  HIV/STIs 1 (1.6) 3 (4.4) 4 (3.1)
  Pain during intercourse 0 3 (4.4) 3 (2.3)
  Cannot name any consequence 17 (27.9) 19 (27.5) 36 (27.7)
*One missing value.
†Open- ended question. Totals may be more than 100%.
‡Participants report: “If you are infected with STIs”, sharing underwear and unprotected sex.
§Participant reports: vaginal medicine.
BV, bacterial vaginosis; HPV, human papilloma virus; IQR, inter- quartile range; STI, sexually transmitted infection.
Table 4 Continued
were not evaluated in our study, although preliminary 
efficacy results in this study were promising.17 We could 
not directly compare experiences with, and opinions 
about, the two different vaginal probiotics because each 
woman used only one product and qualitative data depth 
was suboptimal. In the FGDs/IDIs, it was sometimes diffi-
cult to ascertain whether participants were referring to 
personal experiences or to wider community perceptions. 
Strengths of our study include the use of a mixed- methods 
approach and triangulated adherence data.
COnClusIOns
The prevention of BV recurrence will likely have to 
include several components to be successful, such as 
improved diagnostics, treatments and prophylactic prod-
ucts (for example probiotics), but also improved infor-
mation, education, and counselling messages targeted to 
at- risk women and their partners. The results of this study 
can be used to inform future product development and 
to fine- tune counselling messages in future trials.
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